Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $43.00 to $45.00. They now have an "outperform" rating on the stock.
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity [Seeking Alpha]
Aptevo Therapeutics, TRACON Pharmaceuticals, BioSig Technologies among healthcare movers [Seeking Alpha]
Revolution Medicines, Inc. (NASDAQ: RVMD) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $48.00 price target on the stock, up previously from $36.00.